Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 13/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157726 | 0.88 | ROCK2 (0.59) | ABCG2CSNK2A1KIF11ROCK2ROCK1 | |
| SCHEMBL6153413 | 0.88 | CSNK2A2 (0.62) | ABCG2CSNK2A2CSNK2BCSNK2A1ROCK2 | |
| SCHEMBL6155483 | 0.84 | CSNK2A2 (0.59) | ABCG2CSNK2A2CSNK2BCSNK2A1ROCK2 | |
| SCHEMBL6157444 | 0.81 | ROCK2 (0.67) | CSNK2A2CSNK2BCSNK2A1ROCK2ROCK1 | |
| SCHEMBL6160095 | 0.78 | ROCK2 (0.69) | ABCG2CSNK2A1ROCK2ROCK1 | |
| SCHEMBL6153808 | 0.75 | ROCK2 (0.62) | CSNK2A1ROCK2ROCK1 | |
| SCHEMBL6156315 | 0.74 | ALDH1A1 (0.54) | ABCG2CSNK2A2CSNK2BCSNK2A1ROCK2 | |
| SCHEMBL6153541 | 0.74 | ROCK2 (0.56) | CSNK2A2CSNK2BCSNK2A1ROCK2ROCK1 | |
| SCHEMBL6153835 | 0.74 | ROCK2 (0.64) | CSNK2A1ROCK2ROCK1 | |
| SCHEMBL6153800 | 0.74 | GAA (0.64) | CSNK2A1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | ABCG2 2346/4885CSNK2A2 1209/4885CSNK2B 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.